|
|
Cabling Services
|
AUG1700038421
|
$16,211
|
$16,211
|
N/A
|
N/A
|
|
|
ACM17001-001-00000
|
ACM17001
|
$38,000
|
$38,000
|
UNKNOWN, UNKNOWN
|
|
|
|
ACO13015-001-01002
|
ACO13015
|
$11,862
|
$11,862
|
UNKNOWN, UNKNOWN
|
|
|
|
Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis
|
2R42CA183376-02X1
|
$46,492
|
$46,492
|
Yang
|
"INLIGHTA BIOSCIENCES, LLC"
|
|
|
Exosomal Drug Delivery
|
1R44CA221487-01
|
$719,680
|
$719,680
|
GUPTA, RAMESH
|
3P BIOTECHNOLOGIES, INC.
|
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
1R43CA210817-01A1
|
$152,589
|
$152,589
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
2R44CA162629-02A1
|
$1,154,726
|
$1,154,726
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
1R44CA221539-01
|
$1,206,955
|
$1,206,955
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
|
Novel Materials for Viral Purification
|
1R43CA217454-01A1
|
$224,166
|
$224,166
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
|
Personalized precision dosing of biologic therapies in oncology
|
1R44CA217336-01A1
|
$759,813
|
$759,813
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
|
Development of Tumor Proliferation PET Tracer FLT using a Low Cost Single Dose Automatic Production and Quality Control Biomarker Generator System
|
5R44CA195831-03
|
$711,781
|
$711,781
|
Bruckbauer, Thomas
|
ABT MOLECULAR IMAGING, INC.
|
|
|
OPTION YEAR 1 - PILOT TESTING A HEALTHCARE DELIVERY RESEARCH FELLOWSHIP PROGRAM (TASK 4) AS STATED IN THE SOW
|
261201600638P
|
$38,294
|
$38,294
|
UNKNOWN, UNKNOWN
|
ACADEMYHEALTH
|
|
|
Feasibility of predicting AML response to induction chemotherapy
|
1R43CA221473-01
|
$299,999
|
$299,999
|
HENDERSON, PAUL
|
ACCELERATED MEDICAL DIAGNOSTICS, LLC
|
|
|
Novel Glyco-tests to Predict Chemoresistance
|
1R43CA213766-01A1
|
$297,480
|
$297,480
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
|
Magneto-electronic Sensing of Cancer in Urine
|
1R43CA221535-01
|
$220,000
|
$220,000
|
SANG, LIYUN
|
ACCURE HEALTH, INC.
|
|
|
The Madrina Network Web Portal
|
5R44CA177037-03
|
$688,585
|
$688,585
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
|
Therapeutic disruption of Connexin43-mediated microtubule regulation to target glioblastoma cancer stem cells
|
1R41CA217503-01
|
$224,999
|
$224,999
|
LAMOUILLE, SAMY
|
ACOMHAL RESEARCH, INC.
|
|
|
Minimally invasive image-guided tumor ablation in an oncogenic pig model
|
5R21CA195433-02
|
$266,380
|
$266,380
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
|
Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
1R43CA225169-01
|
$295,205
|
$295,205
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
|
PHOTOACOUSTIC NEEDLE FOR IDENTIFYING TUMOR CONTENT AND MARGINS TO IMPROVE SAMPLING DURING CORE NEEDLE BIOPSY, CAN# 8478658, POP 9/19/2017 - 9/18/2019
|
261201700050C
|
$1,499,895
|
$1,499,895
|
UNKNOWN, UNKNOWN
|
ACTUATED MEDICAL, INC.:1186368
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S2
|
$50,000
|
$50,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
IeDEA West Africa Renewal 3
|
U01AI069919-12
|
$225,000
|
$225,000
|
Dabis, Francois
|
ADERA
|
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
1R43CA217502-01A1
|
$300,000
|
$300,000
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
1R44CA224460-01
|
$299,805
|
$299,805
|
Daunch, William
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
|
Modulation of Immune Checkpoints by Self-Deliverable RNAi for Adoptive Cell Transfer
|
1R43CA213632-01
|
$231,500
|
$231,500
|
WOLFSON, ALEXEY
|
ADVANCED RNA TECHNOLOGIES, LLC
|
|
|
Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes
|
261201700022C*1
|
$299,250
|
$299,250
|
N/A
|
AETHLON MEDICAL, INC.
|
|
|
Peptide-based tool for the rapid isolation of quiescent monocytes from peripheral blood
|
1R43CA211061-01A1
|
$308,839
|
$308,839
|
DARBY, MARTYN
|
AFFINERGY, LLC
|
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
|
Distance Education to Engage Alaskan Community Health Aides in Cancer Control
|
5R25CA186882-04
|
$160,384
|
$160,384
|
CUEVA, MELANY
|
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
|
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
5R01CA129637-07
|
$375,250
|
$375,250
|
DIPERSIO, C. MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
|
Women's Interagency HIV Study (WIHS-V)
|
U01AI035004-25
|
$144,370
|
$144,370
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
|
Central Africa International Epidemiologic Database to Evaluate AIDS
|
U01AI096299-08
|
$260,000
|
$260,000
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
|
20/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048349-25
|
$68,181
|
$68,181
|
CRANDALL, JILL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
|
Einstein-Rockefeller-CUNY Center for AIDS Research
|
P30AI124414-01A1
|
$174,258
|
$174,258
|
GOLDSTEIN, HARRIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-02
|
$520,564
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-04
|
$701,778
|
$701,778
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-05
|
$660,173
|
$660,173
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The sequence recognition, structure and function of the IMP family of mRNA binding proteins
|
1F30CA214009-01A1
|
$49,044
|
$49,044
|
BISWAS, JEETAYU
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Persistent HPV Infection in Women at Risk for Cervix Cancer
|
5U01CA078527-20
|
$581,591
|
$581,591
|
BURK, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center
|
1P20CA210284-01A1
|
$340,631
|
$340,631
|
CASTLE, PHILIP
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-05
|
$346,525
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
1R01CA216248-01
|
$565,675
|
$565,675
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
MOTILITY AND INVASION
|
5P01CA100324-15
|
$2,028,990
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Signal transduction regulating tumor cell dissemination
|
5R01CA150344-29
|
$396,625
|
$396,625
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer
|
5R01CA128943-09
|
$396,625
|
$396,625
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid
|
5R01CA167839-06
|
$346,525
|
$346,525
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
DNA Mismatch repair and cancer in murine models
|
5R01CA076329-21
|
$380,585
|
$380,585
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Designing Novel Anti-Cancer Therapeutics: Targeting Methionine Metabolism
|
1F30CA210372-01A1
|
$49,044
|
$49,044
|
FIRESTONE, ROSS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The role of macroH2A variants in cancer and senescence
|
2R01CA155232-07
|
$382,013
|
$382,013
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-04
|
$346,525
|
$346,525
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Total relevant funding to Cancer for this search: $5,636,393,224
|
